Project Grant HT94252510181
Award Date
4/1/25
Completion Date
3/31/27
Dollars Obligated
$2M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Erie, CO 80516, USA
Similar Awards
This federal Project Grant award of $1,392,575.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports a project by Sola Biosciences, Inc. to develop a protein folding-based gene therapy targeting TDP-43 for the treatment of amyotrophic lateral sclerosis (ALS). The project aims to transform healthcare for military service members and the public through innovative biomedical research, with a focus on developing medical...
This Project Grant award of $498,828.00 from the Defense Health Agency supports the development of a novel treatment strategy and unique methods of delivery to the central nervous system for amyotrophic lateral sclerosis (ALS). The award, effective from July 1, 2023 to June 30, 2025, is funded through the Military Medical Research and Development program (CFDA 12.420), which focuses on transforming health care for Service Members and the public through innovative and impactful biomedical...
This Project Grant award of $2,163,115.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Pathmaker Neurosystems Inc. to develop a noninvasive neuromodulation approach to slow the progression of amyotrophic lateral sclerosis (ALS) by suppressing neuronal hyperexcitability. The research, taking place in Boston, MA, aims to explore this innovative therapeutic method over the 2-year performance...
This federal Project Grant award of $1,072,079.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research by the Massachusetts Institute of Technology (MIT) to develop diagnostic biomarkers for clinical subtypes of amyotrophic lateral sclerosis (ALS). The research aims to advance the understanding and treatment of ALS, a neurological disorder, with potential benefits for military service members and the broader public....
This $2,180,261 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to Projenx Inc., a small disadvantaged business located in New York, NY. The grant funds a Phase 1C clinical study of Prosetin, a novel, brain-penetrant MAP4K inhibitor, in participants with amyotrophic lateral sclerosis (ALS). The study will be conducted over a 2-year period from April 1, 2025 to March 31, 2027. The goal is to advance the...
The Defense Health Agency awarded a $1,210,500 Project Grant to Mayo Clinic under the Military Medical Research and Development program (CFDA 12.420) to explore novel biomarkers for amyotrophic lateral sclerosis (ALS) using a multiomics approach. The award, effective April 1, 2025 through March 31, 2028, will support research involving immunoprofiling, extracellular vesicle analysis, and TDP-43 aggregation assays. This project aims to advance the understanding of ALS pathogenesis and identify...
The federal Project Grant award of $654,391 was provided by the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to Evotec International GMBH. This funding supports a proof of concept study for a molecular glue approach to treat Amyotrophic Lateral Sclerosis (ALS). The project, scheduled from April 2024 to March 2026, aims to develop innovative treatments for neurodegenerative diseases. Evotec International GMBH, a leading drug discovery and development...
The federal Project Grant award of $1,103,084 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is funding the development of a personalized blood-based diagnostic assay for the early detection of amyotrophic lateral sclerosis (ALS). The prime awardee, Arizona State University's Division Orspa, is leading the research effort. The project will run from November 1, 2024 to October 31, 2026.
As a sub-award under this grant, Georgetown University is...
The Department of Defense's Defense Health Agency awarded a $1,035,460 Project Grant to Brigham & Women's Hospital Inc. to conduct research on "TREATMENT OF ALS BY NASAL ADMINISTRATION OF ANTI-CD3 MONOCLONAL ANTIBODY TO MODULATE INFLAMMATORY MICROGLIA AND PREVENT MOTOR NEURON DEGENERATION". This grant, funded under the Military Medical Research and Development program (CFDA 12.420), aims to develop a new treatment approach for amyotrophic lateral sclerosis (ALS) by modulating...
The Defense Health Agency awarded a $1.19 million Project Grant to The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. from May 1, 2023 to April 30, 2026 under the Military Medical Research and Development program (CFDA 12.420).
The grant funds research into targeting excessive sphingolipid synthesis for treatment of amyotrophic lateral sclerosis (ALS) being conducted by Dr. Teresa M. Dunn of the Uniformed Services University of the Health Sciences. Dr. Dunn is...